Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 17, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying chronic hand eczema, a skin condition that can cause itching, redness, and swelling on the hands. Researchers are using advanced techniques to better understand the immune system's role in this condition, which may help identify new ways to treat it. The trial is currently recruiting participants who are between 18 and 65 years old and have had hand eczema for at least three months or have experienced two or more flare-ups in the past year. People with atopic dermatitis affecting their hands, as long as it doesn’t cover more than 30% of their body, may also qualify.
If you decide to participate, you'll undergo tests to help researchers learn more about the immune processes involved in your eczema. However, there are some restrictions on medications: you cannot have taken certain treatments like immunosuppressants or long-term corticosteroids recently. This study aims to gather valuable information that could lead to better treatments for those suffering from chronic hand eczema, so your involvement could make a difference in understanding this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients affected with chronic hand eczema of endogenous and/or exogenous origin, age from 18 to 65 years
- • Patients affected with eczema located on the hands for at least 3 months or with ≥ 2 disease flare-ups in the last year.
- • Patients affected with atopic dermatitis affecting the hands and other areas of the body, provided the eczema lesions involve less than 30% of the body surface area.
- Exclusion Criteria:
- • Concurrent or previous treatment with immunosuppressants, except for short courses of systemic corticosteroids (less than one month of continuous treatment), or biologic agents that may affect the clinical aspects or progression of chronic hand eczema.
- • Patients who have received systemic corticosteroids within one month prior to enrollment in the study.
- • Patients using topical corticosteroids or calcineurin inhibitors within one week of study enrollment (this time frame is considered to provide a good balance between potential residual pharmacological effects and ethical considerations).
- • Patients with chronic hand eczema of mixed etiology (e.g., allergic and atopic) or those considered "etiologically unclassifiable" will not be included in the data analysis.
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, , Italy
Patients applied
Trial Officials
Ketty Peris, Prof
Principal Investigator
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported